Vitamin K (PIVKA-II): Which Tests to Order Alongside and What Results Mean for Women

What Is PIVKA-II and Why Standard Vitamin K Tests Fall Short

PIVKA-II is an undercarboxylated form of prothrombin that accumulates in the blood when cells lack enough vitamin K to complete coagulation-protein synthesis. Its concentration rises before clotting times change and before serum phylloquinone (K1) drops below the lab's reference limit. That makes it the most functionally relevant single marker of vitamin K status available today.

Serum K1 is the test most clinicians order by habit. The problem is that K1 reflects recent dietary intake, not tissue-level sufficiency. A woman who ate a kale salad two days before her draw may show a normal K1 while her bones and vasculature remain chronically under-supplied. PIVKA-II, by contrast, reflects the cumulative functional deficit at the protein level.

Urine Gla-protein (ucOC, undercarboxylated osteocalcin) is another sensitive marker, but it requires specialized assays not widely available in US clinical labs. For most women, PIVKA-II is the accessible, actionable choice.

Why "Normal" PIVKA-II Ranges Are Complicated for Women

Reference intervals matter enormously here, and they are not standardized across platforms. Most published intervals use immunoassay cutoffs of <2.0 ng/mL or <40 mAU/mL, but your lab may use a different assay entirely. Always request the lab-specific reference interval alongside your result.

Sex-specific ranges are rarely reported. The majority of PIVKA-II normative studies enrolled men or mixed cohorts without stratification by menstrual status, hormonal contraception use, or menopausal stage. This is a real evidence gap. When interpreting your own result, ask whether the reference interval your lab used included women of your hormonal status.

The Functional Meaning of a "High" PIVKA-II

A PIVKA-II above your lab's upper reference limit means your body produced prothrombin but could not carboxylate it correctly because vitamin K was functionally unavailable. The degree of elevation roughly tracks severity:

• Mildly elevated (1-2x the upper limit): subclinical deficiency, often diet-related
• Moderately elevated (2-5x): may reflect malabsorption, warfarin effect, or prolonged antibiotic use
• Markedly elevated (>5x): warrants immediate clinical evaluation for liver disease, severe malabsorption, or anticoagulant overdose

The Complete Paired-Test Panel: What to Order Alongside PIVKA-II

Ordering PIVKA-II in isolation answers only one question. The tests below transform that single data point into a clinical picture you can act on.

Bone Health Panel

Carboxylated and undercarboxylated osteocalcin (cOC / ucOC). Osteocalcin is a vitamin K-dependent bone protein. When vitamin K is low, a greater fraction circulates in the undercarboxylated form. The ratio ucOC/total-OC is a direct measure of skeletal vitamin K sufficiency. In one study of 896 postmenopausal women, higher ucOC predicted hip fracture independently of bone mineral density. Ask specifically for both fractions; many labs report only total osteocalcin by default.

CTX-I (C-terminal telopeptide of type-I collagen). CTX-I measures bone resorption rate. Pairing it with PIVKA-II tells you whether deficient vitamin K is occurring alongside accelerated bone breakdown, the combination that matters most for fracture risk in perimenopausal and postmenopausal women.

P1NP (procollagen type I N-terminal propeptide). This is the preferred bone formation marker per the International Osteoporosis Foundation. P1NP and CTX together frame the bone turnover balance; PIVKA-II tells you how well vitamin K can support that formation side.

DEXA scan (dual-energy X-ray absorptiometry). Not a blood test, but the structural endpoint all these markers point toward. ACOG recommends bone density screening at age 65 in average-risk women, earlier if risk factors are present. A T-score below -1.0 in a woman with elevated PIVKA-II is a clear signal to treat both the density deficit and the vitamin K status.

Coagulation Panel

Prothrombin time (PT) and INR. PT/INR reflects the net function of vitamin K-dependent clotting factors (II, VII, IX, X). These become abnormal later than PIVKA-II. A normal PT with an elevated PIVKA-II means you caught the deficiency early. An abnormal PT alongside high PIVKA-II means deficiency is advanced enough to affect hemostasis.

Factor II (prothrombin) activity. More specific than PT alone. Factor II activity below 50% in a woman not on anticoagulants warrants investigation for severe K deficiency or hepatic insufficiency.

Protein C and Protein S. Both are vitamin K-dependent anticoagulant proteins. Protein S deficiency is more clinically significant in women because oral contraceptives and pregnancy independently suppress free Protein S levels. A woman who has low PIVKA-II (rare, and interpreted as adequate K status) but low Protein S may still have a net pro-coagulant state worth evaluating.

Nutritional and Metabolic Panel

25-hydroxyvitamin D. Vitamin D and vitamin K work together on bone mineralization. Deficiency of both is common and synergistic in its harm. The Endocrine Society guideline recommends 25-OH-D testing in women with osteopenia, malabsorption, or limited sun exposure. Target 40-60 ng/mL for bone health in most guidelines, though optimal levels in women remain debated.

Serum calcium and albumin (or ionized calcium). Vitamin K-dependent proteins help regulate vascular calcium deposition. Corrected calcium or ionized calcium alongside PIVKA-II helps distinguish between dietary mineral gaps and functional carboxylation deficits.

Magnesium (RBC magnesium preferred over serum). Magnesium is a cofactor for vitamin D activation and indirectly supports the vitamin K/D/calcium axis. RBC magnesium is more reflective of body stores than serum magnesium.

Comprehensive metabolic panel (CMP). Liver synthetic function (albumin, bilirubin, ALT, AST) is essential context. Because the liver uses vitamin K to make clotting factors, liver disease raises PIVKA-II even when dietary K is adequate. PIVKA-II is, in fact, used as a hepatocellular carcinoma biomarker in some international guidelines, a fact that underscores how elevated values always require a liver function check before attributing the result to diet alone.

Hormonal Panel (Life-Stage Specific)

Estradiol and FSH. Estrogen receptors are present on osteoblasts. Estrogen decline accelerates bone turnover and may reduce the efficiency of vitamin K-dependent bone protein carboxylation. In the Nurses' Health Study, postmenopausal women not on hormone therapy had lower vitamin K intake adequacy and higher fracture rates. FSH and estradiol clarify your hormonal context for interpreting bone marker results.

TSH (thyroid-stimulating hormone). Subclinical hyperthyroidism raises bone turnover markers and vitamin K requirements. Any woman with unexplained elevated CTX or P1NP should have thyroid status confirmed.

Insulin and fasting glucose (or HOMA-IR). Women with insulin resistance or PCOS may have altered vitamin K metabolism. One 2019 study found that dietary vitamin K2 intake was inversely associated with insulin resistance in women with PCOS. Pairing metabolic markers with PIVKA-II is particularly relevant if you are managing PCOS alongside bone or cardiovascular concerns.

PIVKA-II Across the Female Life Stages

Reproductive Years (Ages 18-40)

Vitamin K deficiency is less common in this group but still occurs with restrictive diets, inflammatory bowel disease, celiac disease, or prolonged antibiotic use. Women using hormonal contraceptives should know that estrogen-containing pills modestly suppress Protein S, which can interact with any underlying vitamin K-pathway disruption. Testing is reasonable if you have GI malabsorption, unexplained easy bruising, or a family history of osteoporosis with early onset.

Trying to Conceive and Fertility Workup

Women planning pregnancy may be tested for PIVKA-II as part of a comprehensive nutritional workup. Low vitamin K status before conception has been associated with suboptimal placental vascular development in animal models, though direct human trial data in fertility outcomes is thin. Pair with a full fertility-relevant nutritional panel: folate, B12, vitamin D, iron, and ferritin.

Pregnancy and Postpartum

Vitamin K does not cross the placenta efficiently. Maternal serum K1 and PIVKA-II during pregnancy reflect maternal status only; they do not reliably predict neonatal vitamin K stores. The American Academy of Pediatrics recommends intramuscular vitamin K1 (0.5-1 mg) at birth for all neonates to prevent hemorrhagic disease of the newborn, regardless of maternal vitamin K status. This recommendation applies universally.

Maternal PIVKA-II may be checked in the third trimester if there is concern about malabsorption or cholestatic liver disease, both of which impair fat-soluble vitamin absorption. Pair with PT, albumin, and liver enzymes in that context.

Postpartum and breastfeeding women should know that breast milk is naturally low in vitamin K. Human milk contains approximately 1-4 mcg/L of phylloquinone, far below the infant's daily requirement. The neonatal K1 injection at birth addresses this gap; maternal supplementation does raise milk K1 levels modestly but does not substitute for the neonatal injection.

Perimenopause (Typically Ages 45-55)

This is the highest-yield window for PIVKA-II testing in women without known malabsorption. As estrogen falls, bone resorption accelerates. Vitamin K's role in carboxylating osteocalcin becomes more consequential precisely when the skeletal buffer is thinning.

The WomanRx Perimenopause Bone-Status Panel groups the labs into three tiers based on what each answers:

Tier 1 (order at first perimenopause visit or at first abnormal bone symptom): PIVKA-II, 25-OH vitamin D, CTX-I, P1NP, serum calcium, magnesium, TSH, FSH, estradiol, CBC, CMP

Tier 2 (add if Tier 1 results are abnormal or equivocal): Carboxylated and undercarboxylated osteocalcin ratio, Protein C, Protein S, HOMA-IR, parathyroid hormone (PTH), serum phosphorus

Tier 3 (specialist referral territory): Bone biopsy, DEXA with vertebral fracture assessment (VFA), DXA-based trabecular bone score (TBS), genetic testing for VKORC1 variants if warfarin sensitivity is relevant

This tiered structure means you are not ordering 20 tests simultaneously. You are answering one layer of questions before adding the next.

Postmenopause

Postmenopausal women have measurably lower circulating K1 than premenopausal women, even after adjusting for dietary intake. A cross-sectional analysis of 2,591 women in the Framingham Heart Study Offspring cohort found that low phylloquinone was associated with lower bone mineral density at the femoral neck after menopause. PIVKA-II adds the functional layer that serum K1 misses. Repeat testing annually if supplementation has been initiated, or after any medication change that affects fat absorption or coagulation.

How to Interpret a Low PIVKA-II (Rarely a Problem, but Worth Knowing)

A PIVKA-II below the lower reference limit technically means prothrombin is being fully carboxylated, which suggests vitamin K sufficiency in the coagulation pathway. Most labs do not report a true "low" PIVKA-II because the assay floor represents adequate carboxylation, not a deficiency of the other direction. If your result is reported as undetectable or below assay threshold, that is generally reassuring for coagulation status. It does not rule out subclinical skeletal vitamin K insufficiency, which requires the ucOC/OC ratio for assessment.

How to Lower a High PIVKA-II: Practical Steps

"Lowering" PIVKA-II means correcting functional vitamin K deficiency so that prothrombin can be fully carboxylated.

Dietary Sources

Phylloquinone (K1) is found in highest concentrations in leafy green vegetables. 100 g of cooked kale provides approximately 817 mcg of K1, well above the adult Adequate Intake of 90 mcg/day for women set by the National Institutes of Health Office of Dietary Supplements. Menaquinones (K2), found in fermented foods and some animal products, have longer half-lives and may be more relevant to bone and vascular outcomes. MK-7 (menaquinone-7) from natto has the longest half-life and the most evidence for raising carboxylated osteocalcin.

Supplementation

Standard supplementation doses range from 100-200 mcg/day of MK-7 for bone outcomes in most published trials. The MenaQ7 trial, a 3-year RCT in healthy postmenopausal women, found that 180 mcg/day of MK-7 significantly improved carboxylated osteocalcin levels and attenuated bone mineral density decline at the lumbar spine and femoral neck compared with placebo.

Women on warfarin require specialist supervision before supplementing vitamin K. Vitamin K directly antagonizes warfarin's mechanism. Dose adjustments are needed and are manageable with careful INR monitoring, but self-supplementation without provider involvement is unsafe.

Addressing Root Causes

If PIVKA-II is markedly elevated, diet is rarely the whole story. Investigate:

• Fat malabsorption (celiac disease, Crohn's, cholestatic liver disease, pancreatic exocrine insufficiency)
• Medications: warfarin, broad-spectrum antibiotics, cholestyramine, orlistat, high-dose salicylates
• Liver disease (hepatocellular carcinoma uses PIVKA-II as a tumor marker; markedly elevated values need hepatology input)

Who Should Get PIVKA-II Testing

PIVKA-II is worth ordering if you fall into any of these groups:

• Perimenopausal or postmenopausal women with low bone density (T-score <-1.0) or fracture history
• Women with malabsorptive GI conditions (celiac, IBD, short bowel)
• Women on warfarin who need anticoagulation monitoring beyond INR alone
• Women with PCOS and insulin resistance seeking a comprehensive metabolic-bone workup
• Women with unexplained easy bruising or prolonged bleeding with normal PT
• Pregnant women with cholestatic liver disease in the third trimester
• Women on long-term broad-spectrum antibiotics or medications that impair fat absorption (orlistat, cholestyramine)

Women who do not need routine PIVKA-II testing include those with no bone-risk factors, no malabsorption, no anticoagulant use, and no unexplained bleeding symptoms.

Pregnancy and Lactation: The Section You Cannot Skip

Pregnancy. Vitamin K supplements are not routinely recommended during pregnancy beyond what is included in a prenatal vitamin (typically 75-90 mcg K1). PIVKA-II can be measured safely during pregnancy if clinically indicated. Markedly elevated maternal PIVKA-II in the setting of cholestasis warrants urgent obstetric review because coagulation impairment raises peripartum hemorrhage risk. Vitamin K1 supplementation in pregnant women with documented cholestasis is sometimes given at doses of 5-10 mg/day orally in the third trimester, under specialist guidance.

Neonatal vitamin K hemorrhage prevention. This is non-negotiable. ACOG and the AAP jointly support intramuscular vitamin K1 (1 mg) at birth for all newborns. Parental refusal of neonatal K1 injection is associated with a 81-fold increased risk of vitamin K deficiency bleeding in the infant. Maternal vitamin K status and supplementation do not replace neonatal injection.

Lactation. Breast milk is low in vitamin K by nature. Maternal MK-7 supplementation at 600 mcg/day has been shown to raise breast milk MK-7 concentrations meaningfully, but this does not replace the neonatal K1 injection and is not a standard clinical recommendation. A breastfeeding woman's own PIVKA-II can be checked if she has malabsorption or is on antibiotics long-term; her deficiency is independent of and managed separately from neonatal vitamin K protection.

Contraception note. Vitamin K has no direct interaction with hormonal contraceptives. Women on combined oral contraceptives may have slightly suppressed Protein S levels, which is a separate vitamin K-dependent pathway worth knowing if thrombosis risk is being assessed.

A Note on the Evidence Gap

Women have been systematically underrepresented in nutritional trials, and PIVKA-II research is no exception. Most large PIVKA-II reference studies either enrolled men or did not stratify results by menopausal status, hormonal contraceptive use, or phase of the menstrual cycle. The bone-health trials with MK-7 (including MenaQ7) are notable exceptions because they specifically enrolled postmenopausal women, which gives us the strongest evidence base for that life stage. For reproductive-age women, PCOS populations, and perimenopausal women, data is extrapolated from general adult studies. Ask your clinician whether the reference range your lab used reflects your hormonal status.